Current Report Filing (8-k)
07 Juni 2023 - 10:06PM
Edgar (US Regulatory)
0001812173
false
--12-31
0001812173
2023-06-01
2023-06-01
0001812173
RBOT:ClassCommonStockParValue0.0001PerShareMember
2023-06-01
2023-06-01
0001812173
RBOT:WarrantsToPurchaseOneShareOfClassCommonStockEachAtExercisePriceOf11.50PerShareMember
2023-06-01
2023-06-01
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): June 1, 2023
VICARIOUS
SURGICAL INC.
(Exact
name of registrant as specified in its charter)
Delaware |
|
001-39384 |
|
87-2678169 |
(State or other jurisdiction
of incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
78
Fourth Avenue
Waltham, Massachusetts |
|
02451 |
(Address of principal executive
offices) |
|
(Zip Code) |
Registrant’s
telephone number, including area code: (617) 868-1700
N/A
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐ |
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on
which registered |
Class
A common stock, par value $0.0001 per share |
|
RBOT |
|
The New York Stock Exchange |
Warrants to purchase one
share of Class A common stock, each at an exercise price of $11.50 per share |
|
RBOT WS |
|
The New York Stock Exchange |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.
2021
Equity Incentive Plan
On
June 1, 2023, Vicarious Surgical Inc. (the “Company”) held its 2023 annual meeting of stockholders (the “Annual Meeting”).
At the Annual Meeting, the stockholders approved an amendment to the Company’s 2021 Equity Incentive Plan (the “2021 Plan”)
that includes the following material changes:
| ● | The
aggregate number of shares of the Company’s common stock that may be issued under the
2021 Plan is increased by 6,970,817 shares, subject to adjustment for certain changes in
the Company’s capitalization. |
| ● | The
aggregate maximum number of shares of the Company’s common stock that may be issued
pursuant to the exercise of incentive stock options under the 2021 Plan is increased by 6,970,817
shares, subject to adjustment for certain changes in the Company’s capitalization. |
A
detailed summary of the material features of the 2021 Plan is set forth in the Company’s definitive proxy statement for the Annual
Meeting filed with the Securities and Exchange Commission on April 25, 2023. That summary and the foregoing description of the 2021 Plan
is qualified in its entirety by reference to the full text of the 2021 Plan, a copy of which is filed as Exhibit 10.1 hereto and incorporated
herein by reference.
Non-Employee
Director Compensation Policy
The
Company’s board of directors (the “Board of Directors”) approved an amendment to the Company’s non-employee director
compensation policy (the “Non-Employee Director Compensation Policy”), effective as of June 1, 2023. Pursuant to the amended
policy, non-employee directors receive annual retainers as follows:
Position | |
Retainer | |
Chairperson of the Board (Additional Retainer) | |
$ | 35,000 | |
Member of the Board | |
$ | 40,000 | |
Chairperson of the Audit Committee | |
$ | 18,000 | |
Member of the Audit Committee | |
$ | 6,300 | |
Chairperson of the Compensation Committee | |
$ | 14,250 | |
Member of the Compensation Committee | |
$ | 5,500 | |
Chairperson of the Nominating and Corporate Governance Committee | |
$ | 10,000 | |
Member of the Nominating and Corporate Governance Committee | |
$ | 4,650 | |
These
fees are payable in arrears in quarterly installments no later than the fifteenth day following the end of each calendar quarter, provided
that the amount of such payment will be prorated for any portion of such quarter that a director is not serving on our board of directors,
on such committee or in such position. Non-employee directors may elect to receive a restricted stock unit award with a grant date fair
value of the retainer amounts in lieu of receiving cash in such amounts. Non-employee directors are also reimbursed for reasonable out-of-pocket
business expenses incurred in connection with attending meetings of our board of directors and any committee of the board on which they
serve and in connection with other business related to the board. Directors may also be reimbursed for reasonable out-of-pocket business
expenses in accordance with our travel and other expense policies, as may be in effect from time to time.
In addition, we grant to new non-employee directors upon their initial
election to our board of directors a number of restricted stock units (each restricted stock unit relating to one share of Class A common
stock) having an aggregate fair market value equal to $301,800, determined by dividing (A) $301,800 by (B) the closing price of the Class
A common stock on the NYSE on the date of the grant (rounded down to the nearest whole share), on the date that the non-employee director
is first appointed or elected to our board of directors. Each of these grants shall vest in equal monthly installments over 36 months
from the date of the grant, subject to the non-employee director’s continued service as a director on the applicable vesting dates.
Furthermore, each non-employee director who has been serving on our board
of directors for six months as of the date of any annual meetings of stockholders shall automatically receive a restricted stock unit
award having an aggregate fair market value equal to $145,000, each year on the date of our annual meeting of stockholders. Each non-employee
director who has been serving on our board of directors for less than six months as of the date of any annual meetings of stockholders,
shall automatically receive a restricted stock unit award prorated for the portion of the year served on our board of directors. Each
of these restricted stock unit awards shall vest in equal monthly installments over 12 months from the date of the grant, subject to the
non-employee director’s continued service as a director on the applicable vesting dates.
The
foregoing description of the Non-Employee Director Compensation Policy does not purport to be complete and is qualified in its entirety
by reference to the full text of the Non-Employee Director Compensation Policy, a copy of which is filed as Exhibit 10.2 hereto and incorporated
herein by reference.
Item
5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
On
June 6, 2023, the Company filed a Certificate of Amendment to the Company’s Certificate of Incorporation with the Secretary of
State of the State of Delaware to limit the liability of its officers as permitted by recent amendments to Delaware law (the “Charter
Amendment”).
As
disclosed in Item 5.07 of this Current Report on Form 8-K, the Charter Amendment was approved by the Company’s stockholders at
the Annual Meeting. The foregoing description of the Charter Amendment does not purport to be complete and is qualified in its entirety
by reference to the full text of the Charter Amendment, a copy of which is filed as Exhibit 3.1 hereto and incorporated herein by reference.
Item
5.07 Submission of Matters to a Vote of Security Holders.
On
June 1, 2023, the Company held its Annual Meeting. Of 499,254,534 votes outstanding as of the record date of April 11, 2023, a quorum
of at least 347,176,684 votes, or 69.53% of the votes outstanding and entitled to be cast at the meeting, were present or represented
by proxy.
The
following actions were taken at such meeting:
1. The
following nominees were elected to serve on the Board of Directors until the Company’s 2024 annual meeting of stockholders, based
on the following votes:
Nominee | |
Votes For | | |
Votes Withheld | | |
Broker Non-Votes | |
Adam Sachs | |
| 325,707,056 | | |
| 523,152 | | |
| 20,946,476 | |
Sammy Khalifa | |
| 325,719,137 | | |
| 511,071 | | |
| 20,946,476 | |
David Styka | |
| 317,490,594 | | |
| 8,739,614 | | |
| 20,946,476 | |
Victoria Carr-Brendel | |
| 323,045,394 | | |
| 3,184,814 | | |
| 20,946,476 | |
Ric Fulop | |
| 322,603,617 | | |
| 3,626,591 | | |
| 20,946,476 | |
David Ho | |
| 323,005,109 | | |
| 3,225,099 | | |
| 20,946,476 | |
Beverly Huss | |
| 323,034,951 | | |
| 3,195,257 | | |
| 20,946,476 | |
Donald Tang | |
| 325,877,588 | | |
| 352,620 | | |
| | |
2. The
amendment to the 2021 Plan was approved, based on the following results:
Votes
For |
|
Votes
Against |
|
Abstentions |
|
Broker
Non-Votes |
318,484,525 |
|
7,590,085 |
|
155,598 |
|
20,946,476 |
3. The
Charter Amendment was approved, based on the following results:
Votes
For |
|
Votes
Against |
|
Abstentions |
|
Broker
Non-Votes |
320,233,531 |
|
5,771,038 |
|
225,639 |
|
20,946,476 |
4.
The appointment of Deloitte & Touche LLP as the Company’s independent registered
public accounting firm for the fiscal year ending December 31, 2023 was ratified, based on the following results:
Votes
For |
|
Votes
Against |
|
Abstentions |
|
Broker
Non-Votes |
346,899,198 |
|
152,799 |
|
124,687 |
|
0 |
Item
9.01 Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
VICARIOUS SURGICAL INC. |
|
|
|
By: |
/s/
June Morris |
|
Name: |
June Morris |
|
Title: |
General Counsel and Chief Legal Officer |
Date:
June 7, 2023
4
D8 (NYSE:DEH)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
D8 (NYSE:DEH)
Historical Stock Chart
Von Dez 2023 bis Dez 2024
Echtzeit-Nachrichten über D8 Holdings Corp (New York Börse): 0 Nachrichtenartikel
Weitere Vicarious Surgical Inc. News-Artikel